Dergiler / Journal of Basic and Clinical Health Sciences / 2020 / Cilt: 4 - Sayı: 3

Repositioning of Metformin: Anticancer Agent for Hypoxic Neuroblastoma Cells

Sayfa
384–390
Yayın Tarihi
2020-09-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Metformin treatment has been shown to reduce gene and protein levels of HIF-1α and target molecules in neuroblastoma cells.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives:Neuroblastoma is an extracranial solid tumor of early childhood that has a hypoxic environment.
📊
Temel Bulgular & Veri:The anti-cancer activity of Metformin on SH-SY5Y cells are not fully elucidated.
💡
Sonuç & Katkı:Metformin treatment has been shown to reduce gene and protein levels of HIF-1α and target molecules in neuroblastoma cells.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:neuroblastoma · metformin · hypoxia

Abstract

Objectives:Neuroblastoma is an extracranial solid tumor of early childhood that has a hypoxic environment. VEGF and HIFs molecules play a role in adaptation to this microenvironment. Hypoxic microenvironment leads to poor prognosis and inadequate treatment of neuroblastoma. Metformin has been shown to inhibit tumor growth, might be a potential chemotherapeutic agent. The anti-cancer activity of Metformin on SH-SY5Y cells are not fully elucidated. The aim of this study is to determine the anti-cancer effect of Metformin on SH-SY5Y cells and to elucidate its molecular action mechanism in hypoxia/normoxia. Patients and Methods:SH-SY5Y cells were exposed to increasing doses of Metformin. The viability of SH-SY5Y cells was evaluated using the real time xCELLigence RTCA system. Migration of SH-SY5Y cells was determined using wound healing. The effect of metformin on mRNA and protein expression levels was evaluated using Real-time PCR and Western Blot, respectively. Results:Metformin was observed to significantly reduce the viability of SH-SY5Y cells. Metformin treatment reduced migration of SH-SY5Y cells. In addition, Metformin treatment significantly reduced mRNA expression of HIF-1α, PDK-1 and VEGF-A in SH-SY5Y cells under normoxia and hypoxia. In hypoxia condition, protein expression of HIF-1α and VEGF-A decreased after Metformin administration on SH-SY5Y cells. Protein expression of PDK-1 was observed to decrease in both normoxia and hypoxia conditions on SH-SY5Y cells. Conclusion:In this study, the anti-cancer effect of Metformin on SH-SY5Y cells was determined. Metformin has been observed as inhibitor of migration in SH-SY5Y. Metformin treatment has been shown to reduce gene and protein levels of HIF-1α and target molecules in neuroblastoma cells.

🔖

Bu Makaleye Atıf Yap

SURER, S. I., TOKSOZ, F., BAYRAK, S., MECO, H. E., SEVER, T., BASBİNAR, Y., OLGUN, H. N. (2020). Repositioning of Metformin: Anticancer Agent for Hypoxic Neuroblastoma Cells. Journal of Basic and Clinical Health Sciences, Cilt: 4 - Sayı: 3, 384–390. https://ajindex.com/articles/163508

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649.
  2. Bethesda, MD, 1999. p.69–72. https://seer.cancer.gov/ archive/publications/childhood/childhood-monograph.pdf 2. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Adamson P, Blaney S, Helman L, Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2011. p.886–922. 3. Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078. https://doi.org/10.1038/nrdp.2016.78 4. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381:335–354. [CrossRef] 5. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967–975. [CrossRef] 6. Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining Outstanding Outcomes Using Response and Biology Based Therapy for Intermediate Risk Neuroblastoma. A Report From the Children’s Oncology Group Study ANBL0531. J Clin Oncol 2014;32:10006. [CrossRef] 7. Ishola TA, Chung DH. Neuroblastoma. Surg Oncol 2007;16:149–156. [CrossRef] 8. Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk NB. Pediatr Hematol Oncol 2014;32:26–31. [CrossRef] 9. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33. [CrossRef] 10. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24;469–480. [CrossRef] 11. De Bruycker S, Vangestel C, Staelens S, et al. Effects of metformin on tumor hypoxia and radiotherapy efficacy: a(18F) HX4 PET imaging study in colorectal cancer xenografts. EJNMMI Res 2019;9;74. [CrossRef] 12. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202–2211. [CrossRef] 13. Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015;33:3008–3017. [CrossRef] 14. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1(HIF1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009–1014. [CrossRef] 15. Fontaine E. Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences. Front Endo